Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

ENSOMA

Company Type: Therapeutics

Main focus: In vivo editing via virus-like particles (VLPs) and adenovirus

Company stage: Pre-clinical

Diseases: Targeting any cell of the haematopoietic system to cure diseases from within

Genome-editing tool: Cas12a ( from Twelve Bio)

Funding stage: Series B

Location: Boston USA

Website: ensoma.com

Pipeline:

Partners:

Ensoma is a pre-clinical-stage company that aims to engineer directly haematopoeitic stem cells, T cells and other immune cell types, in vivo, by delivering a genome editor via their proprietary virus-like-particles (VLPs) platform, which is also known as Engenious.

Your Latest CMN News

CMN Weekly (26 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

SNIPR Biome Receives CARB-X Funding to Test...

SNIPR Biome announced today that it has secured funding from CARB-X to further advance SNIPR001 into clinical trials in haematological cancer...

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

Company: ENSOMA

Search CRISPR Medicine